Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase EARLY_PHASE1 2Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 2Depression 1Anxiety Disorders 1

Interventions

Cyclophosphamide 5Positron Emission Tomography Computed Tomography 4pembrolizumab 3Topotecan 2Surveys and Questionnaires 2Psilocybin 2Midazolam 2Methods 2Ketoconazole 2Ketamine 2temsirolimus 1posaconazole 1poly ICLC 1parathyroid hormone-related peptide (1-36) 1lavender oil 1jojoba wax 1ginger extract 1fluoromisonidazole 1fludarabine phosphate 1fludarabine 1fluciclovine F-18 1evolocumab 1etoposide phosphate 1beta-Glucans 1Whole-Body Irradiation 1Vincristine 1Varenicline 1Transplantation 1Transcranial Direct Current Stimulation 1Tetrahydrouridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Neoplasms × Psilocybin × Clear all
NCT04522804 2024-03-20

HOPE

University of Utah

Phase EARLY_PHASE1 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

NCT00957359 2020-10-20

Psilocybin Cancer Anxiety Study

NYU Langone Health

Phase EARLY_PHASE1 Completed
29 enrolled 59 charts

Anxiety Disorders, Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡